{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-21-000225","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2021-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.390440+00:00","generated_at":"2026-06-28T21:17:36.979042+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NeoGenomics appoints Lynn Tetrault as Non-Executive Chair; VanOort to retire from board","bullets":["Douglas VanOort resigned as Executive Chairman and Chair of the Board effective Oct 7, 2021; plans to retire from board by year-end.","Lynn Tetrault, former Lead Independent Director, appointed as Non-executive Chair effective Oct 7, 2021.","Tetrault to receive additional quarterly fee of $15,625 and a $50,000 equity grant for her role as Chair.","VanOort's resignation was not due to any dispute with the Company, management, or Board.","Tetrault brings over 25 years of healthcare experience, including EVP at AstraZeneca."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-21-000225","json":"https://secwatch.observer/filing/0001077183-21-000225.json","markdown":"https://secwatch.observer/filing/0001077183-21-000225.md","text":"https://secwatch.observer/filing/0001077183-21-000225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000225/0001077183-21-000225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000225/neo-20211005.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:17:36.979042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e144515666","claim":"Douglas M. VanOort resigned as Executive Chairman and Chairman of the Board at NEOGENOMICS INC.","evidence_excerpt":"Douglas M. VanOort, the former Chief Executive Officer of NeoGenomics, Inc. (the “Company”) and currently the Company’s Executive Chairman and Chairman of the Board of Directors (the “Board”) of the Company, notified the Board of his voluntary decision to retire from the Company and that in connection with his retirement he was tendering his resignation as Executive Chairman and Chairman of the Board of the Company, effective October 7, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000225/0001077183-21-000225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Chairman and Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"f91178d964","claim":"Lynn A. Tetrault was appointed as non-executive Chair of the Board at NEOGENOMICS INC.","evidence_excerpt":"appointed Lynn A. Tetrault, the Company’s Lead Independent Director, as the non-executive Chair of the Board, effective October 7, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000225/0001077183-21-000225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"non-executive Chair of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}